바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.70 No.5
Citation Share

Issues on Safety of Long-Acting Muscarinic Antagonist

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2011, v.70 no.5, pp.384-389



& (2011). Issues on Safety of Long-Acting Muscarinic Antagonist. Tuberculosis & Respiratory Diseases, 70(5), 384-389.
  • Downloaded
  • Viewed
PDF Download

Abstract

The prevention of and the controlling of symptoms, reductions in the frequency of exacerbations, and disease severity are central to the pharmacologic therapy of chronic obstructive pulmonary disease (COPD). COPD patients are inclined to be older, have more comorbidities, and use polypharmacy as a result. Long-acting inhaled muscarinic antagonists (LAMAs) is a preferred treatment modality. However, the cardiovascular (CV) safety of anti-cholinergics, including LAMA, has been an issue. In contrast, the results of the UPLIFT trial and a pooled analysis of data from 30 trials of tiotropium illustrates the association of tiotropium with reductions in the risk of all cause mortality, CV mortality and CV events. And, the UPLIFT trial provides clues regarding the additive advantages of tiotropium in COPD patients who already are using long-acting inhaled β2 agonists and inhaled corticosteroids. Following the contribution of tiotropium as a first LAMA, new LAMAs such as aclidinium and glycopyrrolate (NVA-237) seem to be emerging.

keywords
Pulmonary disease, Chronic Obstructive, Cholinergic Antagonists, tiotropium, Muscarinic Antagonists, Pulmonary disease, Chronic Obstructive, Cholinergic Antagonists, tiotropium, Muscarinic Antagonists

Reference

1.

1. Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, updated 2010 [Internet]. Bethesda, MD: GOLD; c2010 [cited 2011 May 13]. Available from: http:// www.goldcopd.com/download.asp?intId=617.

2.

2. Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin Pulm Med 2010;16:97-105.

3.

3. Joos GF. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2010;19:257-64.

4.

4. Kim SJ, Kim MS, Lee SH, Kim YK, Moon HS, Park SH, et al. A comparison of tiotropium 18 microgram, once daily and ipratropium 40 microgram, 4 times daily in a double-blind, double-dummy, efficacy and safety study in adults with chronic obstructive pulmonary disease. Tuberc Respir Dis 2005;58:498-506.

5.

5. Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis [Internet]. Silver Spring, MD: US Food and Drug Administration; 2008. [Cited 2011 May 13]. Available from: http://www.fda.gov/ ohrms/dockets/ac/08/briefing/2008-4398b1-01-FDA.pdf.

6.

6. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008;149:380-90.

7.

7. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300:1439-50.

8.

8. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543-54.

9.

9. Celli B, Decramer M, Leimer I, Vogel U, Kesten S, Tashkin DP. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137:20-30.

10.

10. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium-- the FDA's conclusions. N Engl J Med 2010; 363:1097-9.

11.

11. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117(2 Suppl):63S-6S.

12.

12. Valente S, Pasciuto G, Bernabei R, Corbo GM. Do we need different treatments for very elderly COPD patients? Respiration 2010;80:357-68.

13.

13. Spiriva Handihaler package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2010.

14.

14. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006;130: 1695-703.

15.

15. Pedone C, Incalzi RA. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009; 360:185.

16.

16. Chang ET. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009;360:185.

17.

17. O'Connor AB. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009;360:185-6.

18.

18. Singh S, Furberg CD, Loke YK. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2009;360: 186.

19.

19. Lee TA, Wilke C, Joo M, Stroupe KT, Krishnan JA, Schumock GT, et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 2009;169:1403-10.

20.

20. Hochrainer D, Hölz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med 2005;18:273-82.

21.

21. Caillaud D, Le Merre C, Martinat Y, Aguilaniu B, Pavia D. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2007; 2:559-65.

22.

22. Casarosa P, Bouyssou T, Germeyer S, Schnapp A, Gantner F, Pieper M. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther 2009;330:660-8.

23.

23. Hansel TT, Neighbour H, Erin EM, Tan AJ, Tennant RC, Maus JG, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma. Chest 2005;128:1974-9.

24.

24. Sato E, Koyama S, Okubo Y, Kubo K, Sekiguchi M. Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity. Am J Physiol 1998;274:L970-9.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy